NurExone Biologic closes going public transaction on the TSX Venture Exchange
Categories: Corporate and M&A, Hi-Tech, Labor & Employment
Life-changing pharma tech company, NurExone Biologic has closed its going public transaction on the TSX Venture Exchange and will begin trading under the symbol NRX.
The transaction took place via a merger with EnerSpar Corp.
The Gowling WLG team aced as Canadian legal counsel to NurExone Biologic Ltd., with
Irwin Lowy LLP acting for EnerSpar.
Read more here.
